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Abstract
Background: Acute Kidney Injury (AKI) adversely affects outcomes after cardiac surgery. A major mediator of AKI is
the activation of leukocytes through exposure to the cardiopulmonary bypass circuit. We evaluate the use of
leukodepletion filters throughout bypass to protect against post-operative AKI by removing activated leukocytes
during cardiac surgery.
Methods: This is a single-centre, double-blind, randomized controlled trial comparing the use of leukodepletion
versus a standard arterial filter throughout bypass. Elective adult patients undergoing heart valve surgery with or
without concomitant procedures were investigated. The primary clinical outcome measured was the development
of AKI according to the KDIGO criteria. Secondary measures included biomarkers of renal tubular damage (urinary
Retinol Binding Protein and Kidney Injury Molecule-1), glomerular kidney injury (urinary Micro Albumin and serum
Cystatin C) and urinary Neutrophil Gelatinase Associated Lipocalin, as well as the length of hospital stay and quality
of life measures through EQ-5D-5L questionnaires.
Results: The ROLO trial randomized 64 participants with a rate of recruitment higher than anticipated (57% achieved,
40% anticipated). The incidence of AKI was greater in the leukodepletion filter group (44% versus 23%, risk difference
21, 95% CI − 2 to 44%). This clinical finding was supported by biomarker levels especially by a tendency toward
glomerular insult at 48 h, demonstrated by a raised serum Cystatin C (mean difference 0.11, 95% CI 0.00 to 0.23, p =
0.068) in the leukodepleted group. There was however no clear association between the incidence or severity of AKI
and length of hospital stay. On average, health related quality of life returned to pre-operative levels in both groups
within 3 months of surgery.
Conclusions: Leukocyte depletion during cardiopulmonary bypass does not significantly reduce the incidence
of AKI after valvular heart surgery. Other methods to ameliorate renal dysfunction after cardiac surgery need
to be investigated.
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Espeed.Khoshbin1@nhs.net
1Department of Cardiothoracic Surgery, Freeman Hospital, High Heaton,
Newcastle upon Tyne NE7 7DN, UK
Full list of author information is available at the end of the article
Khoshbin et al. Journal of Cardiothoracic Surgery           (2021) 16:58 
https://doi.org/10.1186/s13019-021-01402-4
(Continued from previous page)
Trial registration: The trial was registered by the International Standard Randomized Controlled Trial Number
Registry ISRCTN42121335. Registered on the 18 February 2014. The trial was run by the Bristol Clinical Trials
and Evaluation Unit. This trial was financially supported by the National Institute of Health Research (Research
for Patient Benefit), award ID: PB-PG-0711-25,090.
Keywords: Cardiac surgery, Heart valve, Cardiopulmonary bypass, Acute kidney injury, Leukodepletion
Introduction
Following cardiac surgery the overall incidence of acute
kidney injury (AKI) as defined by RIFLE (Risk, Injury,
Failure, Loss of kidney function) criteria is 23% [1, 2].
Patients undergoing valvular heart surgery are at a par-
ticularly higher risk of AKI [3]. Heart valve surgery is an
independent risk factor for the development of AKI
which has been detected in up to 40% of these patients
[4, 5]. This may be due to a relatively longer period of
cardiopulmonary bypass.
AKI is associated with a twofold increase in mortality,
prolonged ICU stay, chronic ill-health and a 1.6 fold in-
crease in the financial cost of care with the risk to costs
ratio escalating with the severity of AKI [6, 7]. Therefore
AKI significantly and adversely affects prognosis and
health outcome after cardiac surgery [8, 9].
Central to the complex etiology of peri-operative renal
damage is the systemic inflammatory response to cardio-
pulmonary bypass (CPB). The important role of leukocyte
activation in CPB-associated inflammation is universally
recognized [10–13]. It has been previously hypothesized
that the inherent nephrotoxic effect of CPB may be signifi-
cantly reduced by incorporating a leukodepletion filter
into the circuit (LG-6 LeukoGuard® Leukocyte Reduction-
Pall Corporation) to physically remove activated leuko-
cytes [14–17]. However the effectiveness of leukodepletion
in reducing CPB-associated renal impairment has not
been fully evaluated [18].
We tested the hypothesis that leukocyte depletion
during bypass would ameliorate renal injury in pa-
tients undergoing heart valve surgery as this group of
patients have a higher risk of developing bypass re-
lated AKI [4]. Previous study of a low risk cohort
undergoing coronary surgery alone did not demon-
strate clinical benefit [15].
Methods
AKI was defined by Kidney Disease Improving Global
Outcomes (KDIGO) criteria (Table 1) in patients under-
going heart valve surgery.
This single-centre, double-blind study was designed as
an external feasibility trial comparing two parallel
groups. Patients were randomized to receive either a leu-
kodepletion filter or a standard arterial filter as part of
the bypass circuit. The filter was used throughout the
bypass run from start to finish.
The frequency of AKI, clinical and sub clinical data,
health-related quality of life (HRQoL) and resource use
data was investigated and collected. We assessed the sub
clinical effects of leukodepletion through measurement
of urinary and serum biomarkers of tubular and glom-
erular kidney injury. Acute injury to the renal tubules
was assessed by excretion of retinol binding protein
(RBP) in the urine (ELISA methods). This biomarker has
previously been validated in cardiac surgical patients [19,
20]. More recent evidence suggests urinary Kidney In-
jury Molecule-1 (KIM-1) as a superior biomarker (ELISA
method) than RBP [20, 21]. Acute injury to the renal
glomeruli was assessed by urinary micro Albumin (Alb)
through turbimetric assay [22] and by serum Cystatin-C
concentration, with potentially better sensitivity com-
pared to glomerular filtration rate [23]. These bio-
markers allow for early detection of renal injury before
conventional clinical parameters such as blood urea and
serum Creatinine, become abnormal.
Fresh urine samples were collected within strict time
‘windows’ for each biomarker. Urinary RBP, KIM-1 and
Alb were indexed to urinary excretion of Creatinine
(RBP:Cr, Alb:Cr, KIM-1:Cr) to adjust for variations in
the glomerular filtration rate. Urinary Neutrophil Gelati-
nase Associated Lipocalin (NGAL) [24] another bio-
marker used in cardiac surgery to assess associated AKI
Table 1 Kidney Disease Improving Global Outcomes (KDIGO): primary outcome defined by this criterion for acute kidney injury
Stage Serum creatinine (SCr) criteria Urine output criteria
1 Increase ≥26 μmol/L within 48 h or
increase ≥1.5 to 1.9 x reference baseline SCr
< 0.5 mL/kg/hr. for > 6 consecutive hrs
2 Increase ≥2 to 2.9 x reference baseline SCr < 0.5 mL/kg/hr. for > 12 h
3 Increase ≥3 x reference baseline SCr or
increase ≥354 μmol/L or
commenced on renal replacement therapy irrespective of stage
< 0.3 mL/kg/hr. for > 24 h or anuria for 12 h
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and serum Cystatin C was measured as actual
concentrations.
Comparative analyses of levels of biomarkers over time
was carried out using mixed regression models, includ-
ing main effects of group, time and the interaction of
group by time. This allowed for a more precise assess-
ment of AKI than can be achieved using the KDIGO cri-
teria, which does not differentiate between pre-renal
failure (due to volume depletion) and renal damage.
HRQoL was measured using the Minnesota Living
with Heart Failure (MLHF) [25] and EQ-5D-5L ques-
tionnaires enabled the evaluation of both impact on
quality of life and cost (resource use data) in a single
measure [26, 27] up to 3months following surgery.
The sample size was set at 108 participants (54 per
group) who would allow the incidence of AKI to be esti-
mated with the following precision (95% confidence
interval): 31 to 50% for an incidence of 40 and 5% to
17% for an incidence of 10% (Proportions as high as
40%, and as low as 10%, have been reported to have de-
veloped AKI following heart valve surgery). This sample
size also had 95% power to detect a 1.5 fold reduction in
RBP:Cr for the leukodepletion filter group at the 1%
level of statistical significance [15], allowing for 10%
dropout. The 1.5 fold reduction is lower than that ob-
served in a previous study for both RBP:Cr and Alb:Cr
[15], but was considered clinically relevant and appropri-
ate as the previous study may have been at risk of bias.
Inclusion and exclusion criteria are illustrated in
Table 2.
Eligible patients were randomized to either the leuko-
depletion filter (LG-6) or the standard filter group by
the perfusionist using a secure password-protected web-
based interface. The process took place immediately
prior to setting up the appropriate filter in order to
minimize dropout between randomization and surgery.
Randomization was stratified by pre-operative risk of
AKI, estimated using the Cleveland CSA-AKI Severity
Score [16] (four strata, score < 3, 3 to 5, 6 to 8, > 8).
Computer generated random allocations were blocked
using various block sizes. The sequence was prepared in
advance by a statistician independent of the study team.
Participants, surgeons and research nurses were all
blinded to the treatment allocation, only the perfusionist
was aware of the filter used [28, 29].
Standard adult extracorporeal tubing set was used as
per routine practice in conjunction with a D903 Avant
membrane oxygenator (Sorin Biomedica, Gloucester,
UK). In the control group, a standard 40-μm arterial line
filter was incorporated into the extracorporeal circuit
downstream from the pump. This was substituted with
an LG6 leukocyte-depleting filter in the study group.
The circuit was primed with 1500–2000mL Plasmalyte
148 solution, 1 g magnesium sulphate and 5000 IU so-
dium heparin. An S3 Revolution centrifugal pump
(Stöckert Instrumente GmbH, Munich, Germany) deliv-
ered non-pulsatile flow maintained at 2.4 L/min/m2. A
target mean perfusion pressure of 65 mmHg was main-
tained with appropriate use of vasoactive agents. With
an activated clotting time of more than 480 s, CPB was
established with mild hypothermia (lowest core
temperature, 32 °C) and alpha-stat management of acid-
base status during cooling and re-warming. The filter
wacovered and positioned below eye level so that it was
not visible to the surgeon so to avoid un-blinding.
Adverse events (AE) were defined as any unfavorable
and unintended occurrence including an abnormal la-
boratory finding, symptom or disease associated with the
intervention or procedure, regardless of whether it is
considered related to the intervention or procedure that
occurs during the course of the study. Any untoward
medical occurrence that resulted in death, was life
threatening, required prolongation of hospitalization, re-
sulted in persistent or significant disability/incapacity
was recorded as a serious adverse event.
Analyses were based on a pre-specified statistical plan
and performed on an intention-to-treat (ITT) basis.
Continuous data were summarized using mean and
standard deviation (or median and interquartile range if
distributions were skewed) and categorical data as num-
bers and percentages. Continuous longitudinal outcomes
were compared using linear mixed effects models. Model
fit was assessed via standard methods and if inadequate
then transformations or alternative analysis methods
were sought. All analyses used the standard filter group
as the reference group and adjusted for Cleveland AKI
Severity Score (stratification factor). Outcomes were re-
ported as proportions or effect sizes as appropriate with
95% confidence intervals (CI) and likelihood ratio tests
were used to determine statistical significance.
Table 2 Inclusion and exclusion criteria
Inclusion criteria
Adults aged 18–89 years having single or multiple heart valve repair or
replacement as a first time or redo operation as an elective or urgent
procedure (i.e. non-emergency procedure), who are able to give in-
formed consent.
Patients with or without concomitant procedures. Concomitant
procedures may include but are not restricted to: coronary artery bypass
graft (CABG), ascending aortic and/or root replacement, and ablation for
atrial fibrillation.
Baseline urea and creatinine levels are within normal range, defined as
follows: urea 2.5 to 7.8 mmol/L; creatinine 45 to 90 μmol/L for women
and 60 to 110 μmol/L for men.
Exclusion criteria
Baseline eGFR< 30 mls/min/1.73 m2
Patients on renal replacement therapy
Planned deep hypothermic circulatory arrest with cardiopulmonary
bypass switched off
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Biomarker concentrations below the limit of detection
were imputed using the lowest detectable concentration.
All analyses were performed in Stata version 14.0 (Stata-
Corp LP, College Station, Tex) or SAS version 9.3 (SAS
Institute Inc., Cary, NC). The trial was reported accord-
ing to the CONSORT reporting guidelines.
Results
Three hundred ninety-four patients were potentially eli-
gible for the trial. one hundred forty-five patients were
screened and met all the basic eligibility criteria (37, 95%
CI 32 to 42%). Eighty-two agreed to take part in the trial
(57, 95% CI 48 to 65%). Eight patients were found to be
ineligible after consent and 10 were withdrawn. Reasons
for withdrawal at this stage included surgeon preference
(n = 4), clinical condition of the patient (n = 2) and logis-
tical reasons (n = 5), leaving 63 randomized participants,
31 to standard perfusion and 33 to receive a leukodeple-
tion filters (Fig. 1).
There was one treatment crossover from the leukode-
pletion filter to the standard filter, as the pump flow was
considered too high for the leukodepletion LG-6 filter.
This was the only case where un-blinding occurred. One
patient did not receive either intervention as the oper-
ation was abandoned due to an intra operative finding of
a porcelain aorta.
Patient demographics are illustrated in Table 3.
The median age of participants was 72.6 years (inter-
quartile range (IQR) 66.1 to 77.7) and 39/63 (62%) were
male. The median additive European System for Cardiac
Operative Risk Evaluation score (EuroSCORE) was 6.0
(IQR, 4.0 to 7.0) and the median Cleveland AKI severity
score was 2.0 (IQR, 1.0 to 3.0). Overall, characteristics
were well balanced across the treatment groups. The
groups were also equivalent in terms of preoperative co
morbidities, ventricular function and the extent of cor-
onary artery disease based on pre-operative angiogram.
The operative data are demonstrated in Table 4. Iso-
lated valve operations accounted for 33/62 (53%) proce-
dures; the remainder included other procedures, mainly
valve and coronary artery bypass graft (CABG) (21/62;
34%). The majority of patients had an aortic valve re-
placement (47/62; 76%). The peri-operative anesthetic
management was standardized and bypass data was
Fig. 1 Flow of participants. Notes 1: An additional 9th patient was found ineligible based on post-consent criteria but was included in the study based
on repeat bloods taken 2: An additional 65th patient was randomized in error. As this patient did not consent and no further data was collected, this
patient has not been included here.3: 6 week health resource use questionnaire brought in after trial started
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compatible. The median (IQR) total duration of CPB in
minutes for the LG-6 group was 119.0 (97.0, 151.0) ver-
sus 124.0 (107.0, 141.0) for the standard filter group.
Study outcomes are summarized in Table 5.
The incidence of post-operative AKI was reported in 21/
63 (33%) participants (95% CI 22 to 46%). The incidence was
higher in the leukodepletion filter group (14/32; 44% versus
7/31; 23%, risk difference 21, 95% CI − 2 to 44%).
Most patients developed stage 1 AKI (13/20; 65%),
whereas only 10% were classified with stage 3 AKI. One
patient in the leukodepletion filter group required
haemodialysis. Diuretic use and fluid balance over the
first 5 days were similar in the two groups. Only four pa-
tients were not given diuretics during this time.
There was no clear association between the incidence,
severity of AKI and the secondary outcome of length of
stay observed between the two groups (Table 5).
Hospital stay by highest AKI stage is illustrated in
Fig. 2. The median length of stay in intensive care was
47.3 h in the leukodepletion filter group and 48.5 h in
the standard group. The median overall post-operative
hospital stay was 7.7 days and 8.8 days respectively. Two
Table 3 Participant characteristics: overall, characteristics were generally well balanced across the treatment groups
Randomized to leukodepletion
filter (n = 32)
Randomized to standard
Filter (n = 31)
Overall
(n = 63)
n % n % n %
Age (years) Median (IQR) 73.5 (69.6, 77.9) 72.0 (61.5, 76.9) 72.6 (66.1, 77.7)
Male 21/32 66% 18/31 58% 39/63 62%
Black ethnicity 2/32 6% 0/31 0% 2/63 3%
BMI Median (IQR) 27.0 (24.4, 32.3) 29.7 (26.0, 34.6) 27.8 (25.5, 33.3)
EuroSCORE Median (IQR) 6.0 (5.0, 7.0) 6.0 (3.0, 7.0) 6.0 (4.0, 7.0)
Cleveland CSA-AKI score Median (IQR) 2.0 (1.0, 3.0) 2.0 (2.0, 3.0) 2.0 (1.0, 3.0)
ECHO/ANGIOGRAM REPORT
LV function Good (> 50%) 28/32 88% 26/31 84% 54/63 86%
Moderate (30–50%) 4/32 13% 5/31 16% 9/63 14%
Extent of coronary disease None/not investigated 22/32 69% 20/31 64% 42/63 66%
Single 2/32 6% 5/31 16% 7/63 11%
Double 3/32 9% 4/31 13% 7/63 11%
Triple 5/32 16% 2/31 6% 7/63 11%
> 50% disease in left main stem 2/32 6% 2/31 6% 4/63 6%
Table 4 Operative details: the bypass data were compatible
Operation detail Randomized to leukodepletion filter (n = 32) Randomized to standard
filter (n = 31)
Overall
(n = 63)
n % n % n %
Type of surgery Valve 15/31a 48% 18/31 58% 33/62 53%
CABG and valve 11/31a 35% 10/31 32% 21/62 34%
Valve and other 5/31a 16% 3/31 10% 8/62 13%
Valve replacement 26/31a 84% 25/31 81% 51/62 82%
Valve repair 8/31a 26% 7/31 23% 15/62 24%
Valve Replacement Details Aortic 23/26 88% 24/25 96% 47/51 92%
Mitral 3/26 12% 1/25 4% 4/51 8%
Valve Repair Details Mitral 4/8 50% 5/7 71% 9/15 60%
Tricuspid 3/8 38% 2/7 29% 5/15 33%
Pulmonary 1/8 13% 0/7 0% 1/15 7%
BYPASS DATA
Total CPB duration (minutes) Median (IQR) 119.0 (97.0, 151.0) 124.0 (107.0, 141.0) 123.5 (99.0, 146.0)
Details on missing data (Leukodepletion, Standard): (1, 0)
IQR interquartile
a1 patient in the leukodepletion filter group was missing CPB specific data, as this patient was an open and shut case
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Overall (n = 63)
n % n % n % (95% CI)
PRIMARY OUTCOME:
Any AKI At any time 14/32 44% 7/31 23% 21/63 33% (0.22, 0.46)
Prior to discharge 14/29 48% 6/25 24% 20/54 37%
Between discharge and 6 weeks ~ 0/26 0% 1/24 4% 1/50 2%
Highest AKI stage Stage 1 9/14 64% 4/6 67% 13/20 65%
Stage 2 4/14 29% 1/6 17% 5/20 25%
Stage 3 1/14 7% 1/6 17% 2/20 10%
First instance of AKI Day 1 9/14 64% 2/6 33% 11/20 55%
Day 2 4/14 29% 3/6 50% 7/20 35%
Day 3 to discharge 1/14 7% 1/6 17% 2/20 10%
Maximum AKI stage Day 1 6/14 43% 0/6 0% 6/20 30%
Day 2 7/14 50% 5/6 83% 12/20 60%
Day 3 to discharge 1/14 7% 1/6 17% 2/20 10%
SECONDARY OUTCOMES:
Need for haemodialysis 1/32 3% 0/31 0% 1/63 2% (0.0,0.1)
In hospital mortality 2/32 6% 0/31 0% 2/63 3% (0.0,0.1)
Infection complications 5/32 16% 4/31 13% 9/63 14% (0.1,0.3)
Length of post-operative stay Median (IQR) days 7.7 (5.8, 13.9) 8.8 (5.9, 11.7) 7.9 (5.9, 12.0)
CICU length of stay Median (IQR) days 47.3 (24.8, 100.0) 48.5 (26.6, 92.8) 48.5 (25.0, 98.3)
Ward length of stay Median (IQR) days 120.8 (94.0, 168.8) 141.5 (92.0, 188.4) 121.3 (93.5, 187.0)
Fig. 2 Probability of remaining in hospital by AKI stage for each of leukodepletion versus the standard filter group. Kaplan-Meier plot showing no
clear association between the incidence, severity of AKI and the secondary outcome of length of stay observed between the two groups and
highest AKI stage
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patients in the leukodepletion filter group died during
their post-operative stay. This was not directly related to
the use of the filter. Infective complications occurred in
9/63 (14%) patients, with a similar incidence in both
groups (leukodepletion filter 16%, standard filter 13%).
Biomarker comparisons are summarized in Fig. 3.
The urinary RBP:Cr and KIM-1:Cr ratios were, on
average, tended to be higher in the leukodepletion filter
group compared to standard filter group (geometric
mean ratio (GMR) 1.16, 95% CI 0.80 to 1.69, p = 0.45
and 1.15, 95% CI 0.87 to 1.52, p = 0.35 respectively). A
proportion of samples were below the limit of detection
for KIM-1:Cr, i.e. below 0.156 ng/ml (46/338 observa-
tions, 13.7%). Urinary NGAL and Alb:Cr ratio were, on
average, lower in the leukodepletion group (geometric
mean ratio (GMR) 0.80, 95% CI 0.54–1.18, p = 0.29 and
0.84, 95% CI 0.51–1.39, p = 0.53). None of the differ-
ences were statistically significant. Serum Cystatin C
concentration was the only biomarker where the differ-
ence between the groups varied significantly with time
(p = 0.011). After adjustment for pre-operative AKI se-
verity, the data suggest a possible difference at 48 h
(mean difference 0.11, 95% CI 0.00 to 0.23, p = 0.068)
with higher average values in the leukodepletion groups,
but not at other times.
Comprehensive resource use data were collected. EQ-
5D- 5 L scores were missing for ≤3 (5%) patients at each
time point (patients who died were assigned a score of
zero for each time point after death). The mean (SD)
EQ-5D single summary index scores for the cohort as a
whole were 0.82 (0.15) preoperatively, and 0.72 (0.24),
0.78 (0.22) and 0.85 (0.22) at 5 days, 6 weeks and 12
weeks respectively, indicating that HRQoL improved
with time after surgery. The MLHF scores showed a
similar pattern.
The overall scores and the scores for both the physical
and emotional subscales reduced from 5 days to 12
weeks indicating HRQoL improved over time (mean
(SD)): overall score at baseline 37.4 (23.0), 5 days 45.6
(25.1), 6 weeks 29.6 (19.6), 12 weeks 16.2 (16.3). Re-
source use during follow up was captured for 36/38
(95%) participants at 6 weeks and 57/61 (93%) partici-
pants at 3 months.
Overall, 3% of resource use data were missing: 1% for the
in-patient period (which had the greatest number of resource
use variables), 5% for follow up to 6weeks, and 8% of follow
up data to 3months. On average, health related quality of life
returned to pre-operative levels by 3months.
A total of 203 adverse events (Supplementary material)
were reported in 58 participants in the first 3 months
after surgery, 66 of which were classified as serious ad-
verse events (SAE). Forty SAEs were reported in 13 pa-
tients in the leucodepletion filter group compared to 26
SAEs in 13 patients in the standard filter group. Of the
203 adverse events reported, 182 were expected compli-
cations after cardiac surgery, i.e. they were listed in the
Fig. 3 Relationship between the biomarkers of acute kidney injury studied in urine and serum with time. Serum Cystatin C was the only marker
that showed significant raise in leukodepleated patients at 48 h post-surgery. (RBP = Retinol binding protein, KIM-1 = Kidney injury molecule − 1,
Alb = micro Albumin, NGAL = Neutrophil gelatinase-associated lipocalin)
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study protocol, and 21 were unexpected. Approximately
one third of SAEs occurred after hospital discharge;
SVT/AF requiring treatment was the most frequently re-
ported SAE, which occurred in 5 participants (8%).
These differences however did not reach significance.
Discussion
Cochrane systematic review by the authors, failed to
identify good quality trials in support of using leukode-
pletion in cardiac surgery in order to inform recommen-
dations for a change in practice for its routine use [18].
Therefore this randomized trial was intended as a feasi-
bility experiment to estimate key clinical, sub clinical
and statistical parameters needed to design a larger more
definitive trial in this subject.
However the results did not support the hypothesis
that leukodepletion throughout cardiopulmonary bypass
would reduce inflammatory response by removing acti-
vated leukocytes.
The incidence of the primary outcome of AKI was al-
most 1.5 times higher in the leukodepletion group com-
pared to the standard. Serum levels of secondary
outcome of Cystatin C showed evidence of subclinical
AKI in the leukodepletion group as compared to the
standard. However this did not translate into a differ-
ence in hospital stay or post procedural quality of life
between the groups.
The study was conducted in a single centre so it may
be more challenging to achieve similar compliance in a
multi-centre setting. However, as was demonstrated in
the Titre-2 trial, with good engagement with study cen-
ters and participants excellent compliance with follow-
up is achievable [30].
The incidence of AKI (the primary outcome) was 33%
which is consistent with previous reports [7], but notably
higher than the 13.2% incidence reported in the Titre-2
trial which recruited 2000 cardiac surgery patients across
17 UK centers [31]. This could be explained by the dif-
ferences in study cohort (41% of patients in Titre-2
underwent isolated CABG surgery). In the subgroup of
the Titre-2 cohort who underwent valve surgery (603
participants) the incidence was 13.8 and 4.3% were AKI
stage 1 (personal communication).
In ROLO the primary outcome could not be calculated
definitively for 9/63 participants due to the Creatinine
not being measured at the 6 week follow-up visit. This is
a limitation, but with only one patient (2%) developing
AKI after discharge, not apparent immediately after sur-
gery, it is unlikely that the cases with missing data would
have experienced AKI.
Blinding of clinical teams to the intervention was suc-
cessful and the treatment was delivered as planned, with
only one cross-over for clinical reasons. There were 4
withdrawals after consent due to surgeon preference,
reflecting the challenge of conducting a clinical trial in
surgery.
Serum Cystatin C concentration was the only bio-
marker where the difference between the groups varied
significantly with time indicative of renal insult at 48 h.
The anticipated 1.5 fold reduction in RBP:Cr in the leu-
kodepletion group [15] was not borne out in this study.
Contrary to expectation the biomarker concentration
was on average 16% higher in the leucodepletion filter
group. The Alb:Cr ratio was lower in the leucodepletion
group, but on average less than anticipated (GMR 0.84
against a target of 0.66). A significant proportion of
KIM-1, samples were below the detection limit i.e. below
0.156 ng/ml (46/338 observations, 13.7%). However a
sensitivity analysis omitting values below the limit of de-
tection was consistent with the primary analysis.
Numerous factors contribute to the development of
renal injury, including reductions in renal blood flow, ac-
tions of nephrotoxic drugs, injury to the proximal tubule
epithelial cells, pro-inflammatory responses of renal
endothelial cells, influx and activation of inflammatory
leukocytes that further reduces renal blood flow through
vascular congestion and promotes kidney injury [32, 33].
Although numerous studies have demonstrated the det-
rimental role of neutrophils, recent reports have uncov-
ered a protective and possibly therapeutic role of
neutrophils in AKI. Studies in animal models have re-
vealed that neutrophils promote renal injury. In contrast,
neutrophils are critical mediators of innate immunity.
They respond rapidly (within minutes) to invading path-
ogens and to sites of tissue damage. Neutrophils clear
invading pathogens by phagocytosis or by releasing toxic
granules containing proteases and other enzymes and re-
active oxygen species (ROS). For this reason, neutrophil
depletion can lead to damage of host cells in the in-
flamed tissue. In several animal models, neutrophil accu-
mulation in the injured kidney is a consistent and early
finding and depletion of neutrophils or prevention of
neutrophil tracking to the kidney reduces kidney injury.
However, these results may be related to differences in
experimental models and limitations to methods for
neutrophil depletion. In addition neutrophils releasing
pro-inflammatory cytokines, interferon IFN-γ and inter-
leukin IL-17, and the chemokine CXCL1, in the injured
kidney [34–36] and direct or indirect release of anti-
inflammatory cytokines IL- 6 IL-10, etc. may suggest a
more complex balance of pro and anti-inflammatory
mechanism of neutrophils related pathogenesis of kidney
injury.
Conclusion
The ROLO trial has demonstrated that a higher inci-
dence of AKI and raised biomarkers of renal injury are
associated with the use of a leukodepletion filter.
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Addition of a leukodepletion filter to the bypass circuit
for valvular heart surgery cannot be supported for the
purpose of limiting post-operative renal dysfunction.
Other interventions to reduce the incidence of this im-
portant complication should be explored.
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